Further investigation into the differential mechanisms of PDE1A and PDE1C in cardiac hypertrophy and HF will aid in developing PDE1 isozyme-selective inhibitors to achieve specific pharmacological effects. This evidence concerns the gene PDE1C and cardiac hypertrophy.